The Top Line

Making sense of China’s R&D ascent


Listen Later

With an uptick in licensing deals and promising data emerging from China-based biopharmas, especially in oncology, it’s clear the country is poised to play a major role in life sciences for the foreseeable future.

In this week’s episode of "The Top Line," we trace China’s ascent in R&D and drug discovery and examine how U.S. and European drugmakers are capitalizing on the momentum through a surge in licensing activity.

Fierce Pharma’s Fraiser Kansteiner sits down with Mark Lansdell, director at Evaluate, to break down the policies fueling China’s growth, how global companies are engaging with Chinese assets and which modalities and indications are commanding the most attention.

To learn more about the topics in this episode: 

  • China approves 4 new drugs, including a global first-in-class medicine
  • With China approval, Lilly and Innovent's mazdutide breaks into new class for GLP-1 obesity drugs
  • China biotechs ‘reshaping’ US biopharma as outlicensing deals rise 11%: Jefferies report
  • China proposes shorter clinical trial reviews in efforts to accelerate drug development

See omnystudio.com/listener for privacy information.

...more
View all episodesView all episodes
Download on the App Store

The Top LineBy Fierce Life Sciences

  • 3.8
  • 3.8
  • 3.8
  • 3.8
  • 3.8

3.8

8 ratings


More shows like The Top Line

View all
WSJ Your Money Briefing by The Wall Street Journal

WSJ Your Money Briefing

1,714 Listeners

The McKinsey Podcast by McKinsey & Company

The McKinsey Podcast

378 Listeners

a16z Podcast by Andreessen Horowitz

a16z Podcast

1,040 Listeners

Exchanges by Goldman Sachs

Exchanges

976 Listeners

Odd Lots by Bloomberg

Odd Lots

1,795 Listeners

Macro Musings with David Beckworth by Mercatus Center at George Mason University

Macro Musings with David Beckworth

378 Listeners

The Long Run with Luke Timmerman by Timmerman Report

The Long Run with Luke Timmerman

121 Listeners

The Readout Loud by STAT

The Readout Loud

317 Listeners

Inside the Strategy Room by McKinsey & Company

Inside the Strategy Room

163 Listeners

Why It Matters by Council on Foreign Relations

Why It Matters

865 Listeners

Business Of Biotech by Ben Comer

Business Of Biotech

88 Listeners

BioCentury This Week by BioCentury

BioCentury This Week

30 Listeners

Raising Health by Andreessen Horowitz, a16z Bio + Health

Raising Health

144 Listeners

Biotech Hangout by Daphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler & more

Biotech Hangout

18 Listeners

Ground Truths by Eric Topol

Ground Truths

50 Listeners